Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon (NASDAQ: ANNX) has granted stock options to nine new non-executive employees under its 2022 Employment Inducement Award Plan. The equity awards, approved on December 10, 2024, comply with Nasdaq Listing Rule 5635(c)(4). The grants total 901,000 shares of Annexon common stock with an exercise price of $4.44 per share, based on the closing price on December 13, 2024. The options have a ten-year term and vest over 4 years, with 25% vesting after the first year and the remaining vesting monthly at 1/48th, contingent on continued employment.
Annexon (NASDAQ: ANNX) ha concesso opzioni su azioni a nove nuovi dipendenti non esecutivi nell'ambito del suo Piano di Indennizzo per l'Occupazione 2022. I premi azionari, approvati il 10 dicembre 2024, sono conformi alla Regola di Quotazione Nasdaq 5635(c)(4). Le concessioni ammontano a 901.000 azioni di azioni ordinarie di Annexon con un prezzo di esercizio di 4,44 $ per azione, basato sul prezzo di chiusura del 13 dicembre 2024. Le opzioni hanno un termine di dieci anni e maturano in 4 anni, con il 25% che matura dopo il primo anno e il restante matura mensilmente a 1/48, a condizione di continuare l'impiego.
Annexon (NASDAQ: ANNX) ha otorgado opciones sobre acciones a nueve nuevos empleados no ejecutivos bajo su Plan de Inducción a la Empleabilidad de 2022. Las compensaciones en acciones, aprobadas el 10 de diciembre de 2024, cumplen con la Regla de Cotización 5635(c)(4) de Nasdaq. Los otorgamientos suman 901,000 acciones de acciones ordinarias de Annexon con un precio de ejercicio de $4.44 por acción, basado en el precio de cierre del 13 de diciembre de 2024. Las opciones tienen un plazo de diez años y se consolidan durante 4 años, con un 25% de consolidación después del primer año y el resto consolidándose mensualmente a 1/48, dependiendo de la continuación del empleo.
Annexon (NASDAQ: ANNX)은 2022년 고용 유인 보상 계획에 따라 아홉 명의 신규 비상근 직원에게 주식 옵션을 부여했습니다. 이 자산 보상은 2024년 12월 10일에 승인되었으며, Nasdaq 상장 규칙 5635(c)(4)를 준수합니다. 부여된 옵션 총액은 901,000주의 Annexon 보통주로, 2024년 12월 13일의 종가를 기준으로 $4.44의 행사 가격이 설정되어 있습니다. 옵션의 유효기간은 10년이며, 4년에 걸쳐 분할되며, 첫 해에 25%가 분할되고 나머지는 지속적인 고용 조건에 따라 매달 1/48씩 분할됩니다.
Annexon (NASDAQ: ANNX) a accordé des options sur actions à neuf nouveaux employés non exécutifs dans le cadre de son Plan de Récompense pour l'Emploi 2022. Les attributions d'actions, approuvées le 10 décembre 2024, sont conformes à la Règle de Cotation 5635(c)(4) de Nasdaq. Les attributions totalisent 901 000 actions de l'action ordinaire d'Annexon avec un prix d'exercice de 4,44 $ par action, basé sur le prix de clôture du 13 décembre 2024. Les options ont une durée de dix ans et sont acquises sur 4 ans, avec 25 % acquises après la première année et le reste acquises mensuellement à raison de 1/48, sous condition de maintien de l'emploi.
Annexon (NASDAQ: ANNX) hat neun neue nicht-executive Mitarbeiter im Rahmen seines Beschäftigungsanreizprogramms 2022 Aktienoptionen gewährt. Die Aktiendotierungen wurden am 10. Dezember 2024 genehmigt und entsprechen der Nasdaq Notierungsregel 5635(c)(4). Die Zuwendungen umfassen insgesamt 901.000 Aktien von Annexon-Stammaktien mit einem Ausübungspreis von 4,44 $ pro Aktie, basierend auf dem Schlusskurs vom 13. Dezember 2024. Die Optionen haben eine Laufzeit von zehn Jahren und vesten über einen Zeitraum von 4 Jahren, wobei 25% nach dem ersten Jahr vesten und der Rest monatlich im Verhältnis 1/48 vestet, abhängig von der Fortsetzung des Arbeitsverhältnisses.
- Successful attraction of new talent with equity-based compensation
- Implementation of structured employee retention program through long-term vesting schedule
- Potential future dilution of existing shareholders through 901,000 new stock options
BRISBANE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to nine new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on December 10, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
In the aggregate, the new non-executive employees received options to purchase 901,000 shares of Annexon common stock. The options carry a ten-year term and an exercise price per share equal to
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is harnessing classical complement-driven neuroinflammation to advance potentially first-in-kind treatments for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. Our novel scientific approach focuses on C1q, the initiating molecule of classical complement’s potent inflammatory pathway that when misdirected can lead to tissue damage and loss. By targeting C1q, our immunotherapies are designed to stop neuroinflammatory diseases where they start. Our pipeline spans three diverse therapeutic areas – autoimmune, neurodegenerative and ophthalmic diseases – and includes targeted investigational drug candidates designed to address the unmet needs of over 8 million people worldwide. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
FAQ
How many shares were granted in Annexon's (ANNX) December 2024 employee inducement grants?
What is the exercise price for Annexon's (ANNX) December 2024 inducement stock options?
What is the vesting schedule for Annexon's (ANNX) December 2024 inducement grants?
When do Annexon's (ANNX) December 2024 inducement stock options expire?
